First Patient Enrolled at Memorial Sloan Kettering Cancer Center in PCCTC-Sponsored TALENT Study Evaluating Novel Treatment Combination for Advanced Prostate Cancer

The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that investigators at Memorial Sloan Kettering Cancer Center (MSK) have enrolled the first patient in the TALENT study, a randomized Phase 2 clinical trial examining combination therapy for patients with metastatic Androgen Pathway Modulator-Resistant prostate cancer (formerly metastatic castration-resistant prostate cancer (mCRPC)) and specific genetic mutations (NCT06844383).

The TALENT study (TALazoparib with or without ENzalutamide) will evaluate whether adding enzalutamide to talazoparib therapy improves outcomes for patients with homologous recombination repair (HRR) gene mutations who have experienced disease progression while receiving abiraterone acetate treatment.

“This study addresses a critical clinical question for patients whose cancer has progressed on current standard treatments including ADT and abiraterone acetate with prednisone," said Dr. Karen Autio, co-principal investigator at Memorial Sloan Kettering Cancer Center. "We're investigating whether this combination approach can extend progression-free survival for patients with specific genetic profiles."

The multicenter trial, co-led by investigators at MSK (Dr. Karen Autio) and Dana-Farber Cancer Institute (Dr. Alicia Morgans) with trial management by the PCCTC, plans to enroll up to 126 patients with HRR mutations including BRCA1, BRCA2, ATM, and other DNA repair genes. Participants will be randomized to receive either talazoparib alone or talazoparib combined with enzalutamide. Unlike prior studies of this combination, this trial will address contemporary practice patterns where patients receive ADT as well as an androgen pathway signaling agent in the first line setting.

The study is sponsored and conducted through the PCCTC and funded by Pfizer.

For more information about the TALENT study, contact the PCCTC at pcctctalent@mskcc.org .